Search

Invest with us

Invest with us in New S-Pharma mRNA vaccine and Smart medicines R&D factory and become Shareholder - Pre IPO Investment -

  • S-Pharma - Investment in Biopharmaceutical R&D factory for vaccine and medicines. 
  • Discovering, developing and providing different branche of vaccines and medicines. 
  • Location of Investment: East Europe. European Union (EU) 
  • Production Plan: over 200 million vaccines/month (2.4 billion vaccines yearly)
  • Investment in cooperation with Grafin Invest 
  • Investment process for S-Pharma London in cooperation and supervises with Grafin Invest Project.
  • The development is due to complete in Q4 2022/Q2 2023

S-Pharma New Vaccine R&D Factory - become shareholder

Brand new Biopharmaceutical R&D (research & development) factory with vaccine and medicines factory.
  • Type of business: Biopharmaceutical R&D (research & development) factory for mRNA vaccine and smart medicines. 
  • The development is due to complete in Q4 2022/Q2 2023 Location of Investment: European Union (EU) 
  • Full Investment (Capital cost): 640.000.000 € based on one large R&D Factory for Vaccine and medicines. 
  • Holdings: Total of 640 Share at 1.000.000 €. 
  • Min. investment 10.000.000 € for 10 share and 10 Voting Rights 
  • Max. Investment 279..000.000 € for 279 Share 
  • One Share are One voting Rights. 
  • Vaccine factory stocks give additional income, or you can sell it at a higher price per share and earn from it as well. 
  • Our project report also maintains that will grow by over next five years with Up to 24% return pro year. 
  • International management team with record of success.
Ownership  of shares (until now): 
  • S-Pharma U.K. own 160 share (25% ownership) 
  • Live Insurance Company U.K (data known to management) 64 share 
  • Pharmaceutical Company (data known to management) 30 share 
  • Pharmaceutical Company 2 (data known to management) 10 share 
  • Investment funds (two Investment fund from USA and EU) (data known to management) 40 share 
  • Investment Bank (data known to management) 29 share 
  • Private Investor (data known to management) 28 share (Investor from: Suisse, UK, USA, Russia, Germany, UAE, SA, China, Italy, Bahrain, Poland, Kuwait, Croatia, Spain, Israel, Netherland, Sweden, Norvege, Danemark and Island 
  • Free for investors: 279 share 
  • Every Investor have "Memorandum and Articles of Association" and shareholder certify 
  • One Share are One voting Rights 
  • Project number: 888 048
  • Investment process for S-Pharma London controls and supervises Grafin Invest

Project documentation for investors:

  • Complete project documentation of Biopharmaceutical R&D (research & development) factory for mRNA vaccine and smart medicines. 
  • Financial Analysis 
  • Feasibility 
  • Technical calculation 
  • Designing 
  • Supervision 
  • Installation 
  • Miscellaneous 
  • Support Structure 
  • Specification 
  • 2.000,000 € for complete project documentation for investors 
  • If you buy a share the money for project documentation is returned

Invest with us

  • Production Plan: 200 million vaccines/month (2.4 billion vaccines yearly)
  • Location of Investment: East Europe. European Union (EU) 
  • The development is due to complete in Q4 2022/Q2 2023

Why Invest with us?

S-Pharma, a United Kingdom company for the manufacturing and sale of pharmaceutical products. Fully operational Pharmaceutical Production Facilities with all standards/certificates. Our project report also maintains that will grow by over next five years with Up to 24% return pro year.
S-Pharma - Investment in New Advanced Research and Development (SARD) Biopharmaceutical factory, for vaccine and medicines. and S-Pharma entered a public-private partnership to establish our Center for Innovation in Advanced Development and Manufacturing. 
Discovering, developing and providing different branche of medicines and vaccines. The SARD facilitates advanced development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures and ensures domestic manufacturing surge capacity.
S-Pharma Inc. are member of Sentange Group London U.K.
  • Vaccines are one of the greatest public health success stories in history. 
  • S-Pharma and its legacy companies and our partners have been working to discover and develop vaccines. Our vaccines have helped prevent a number of diseases, including ones never thought preventable. Today, we remain dedicated to the complex business of researching and producing vaccines. 
  • Now S-Pharma and our partners have been working to discover and develop coronavirus vaccines.
  • BCG Vaccine
  • VARICELLA VACCINE
  • MMR VACCINE
  • DTP VACCINE
  • INFLUENCA VACCINE
  • PNEUMO VACCINE
  • ROTA VACCINE
  • EVAC (Ebola Vaccine)
  • CORONAVIRUS COVID19 VACCINE
MEDICINES: 
Consumer & Prescription medicine
  • CHC – Consumer Healthcare
  • Rx – Prescription medicine

Invest with us

Invest in new Biopharmaceutical R&D (research & development) factory with vaccine and medicines factory. Investment process for S-Pharma London controls and supervises Grafin Invest Project